axona previously marketed medical food clinical dietary management impairment metabolic processes associated mild moderate alzheimers disease proprietary formulation fractionated palm kernel oil caprylic triglyceride mediumchain triglyceride company makes axona states digestion caprylic triglyceride broken ketones provide alternative energy source brain use based idea brains ability use normal energy source glucose impaired alzheimers disease axona first sold march us food drug administration fda determined axona misbranded product labeled marketed medical food meet statutory definition medical food axona approved fda drug treat alzheimers efficacy managing health alzheimers patients use medical food questioned experts field including alzheimers association axona medical food marketed assist dietary management mild moderate alzheimers axona formulated oral administration sold prescription largest ingredient axona caprylic also known fractionated coconut oil mediumchain caprylic triglyceride generally recognized safe gras medical food us official fda product classification originally defined congress part orphan drug amendments food formulated consumed administered feeding tube supervision physician intended specific dietary management disease condition distinctive nutritional requirements based recognized scientific principles established medical medical foods drugs marketed treating preventing disease condition fda evaluate efficacy safety medical alzheimers disease clinically characterized progressive decline memory language pathologically accumulation senile plaques neurofibrillary tangles alzheimers disease also characterized reduced ability areas brain use scientists proposed treatments targeting metabolic deficits brain alzheimers patients may makers axona claim oral administration axona caprylic triglyceride axona processed enzymes gut resulting mediumchain fatty acids mcfas absorbed blood supply leading liver mcfas rapidly pass directly liver undergo oxidation form ketones since liver use ketones released circulation used nonliver tissues ketones cross bloodbrain barrier taken brain cells glucose brains chief energy source ketones normally serve backup energy ketones act alternative energy source brain cells impaired ability use glucose sugar result alzheimers makers axona claim may medical benefitscitation needed axona evaluated phase ii clinical trials paid conducted cerecin one published openaccess journal product launched administered patients story abc news noted widespread concern axona medical community calling snake theory brain alzheimers disease patients better able use ketones glucose widely accepted among ad clinicians alzheimers association classified axona alternative treatment expressed concern enough evidence assess potential benefit medical foods alzheimer disease notes safety axona regulated way drugs glenn smith phd clinical neuropsychiatrist mayo clinic also noted axonas safety efficacy known noted alzheimers association doesnt recommend use medical foods including axona treatment alzheimers fda determined axona misbranded section federal food drug cosmetic act usc labeling false misleading product labeled marketed medical food meet statutory definition medical httpsenwikipediaorgwikiaxona